⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AIM News
AIM ImmunoTech Inc.
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
globenewswire.com
AIM
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
globenewswire.com
AIM
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026
globenewswire.com
AIM
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
globenewswire.com
AIM
AZN
Aimbridge Hospitality Earns Multiple Wins at 2025 HSMAI Adrian Awards for Marketing Excellence
businesswire.com
AIM
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering
globenewswire.com
AIM
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
globenewswire.com
AIM
AIM ImmunoTech Announces Commencement of Rights Offering
globenewswire.com
AIM
JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026
accessnewswire.com
AKTX
DCOY
GRI
MBRX
AIM
BULL
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
globenewswire.com
AIM